A team at Memorial Sloan Kettering Cancer Center (MSK) has uncovered several mechanisms of immune escape that can help explain why ovarian cancers have been resistant to immunotherapy to date.
Dec 15, 2022
0
52
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...
Sep 20, 2018
0
60
Patterns of genetic mutation in ovarian cancer are helping make sense of the disease, and could be used to personalise treatment in future.
Aug 14, 2018
0
83
Early diagnosis of high-grade serous ovarian cancer (HGSOC) seems feasible through analysis of genomic alterations in DNA from Papanicolaou (Pap) test smears, according to a study published online Dec. 6 in Science Translational ...
Dec 11, 2023
0
0
A targeted drug combination for patients with a type of ovarian cancer could be nearly twice as effective as the next best treatment, according to interim results from a phase II study.
Jun 5, 2023
0
14
Researchers associated with SEngine Precision Medicine, a precision oncology company that matches patients to medicines based on their own tumor samples, have published a new case report showing a patient's remarkable response ...
May 24, 2023
0
3
The GOG Foundation, Inc. (GOG) announced positive results from an investigator-initiated phase II trial, sponsored by the GOG, investigating the combination of ribociclib and letrozole in patients with recurrent low-grade ...
Mar 27, 2023
0
5
An artificial intelligence (AI) model may help predict clinical outcomes at the time of laparoscopic assessment for advanced high-grade serous ovarian cancer (HGSOC), according to a study presented at the Society of Gynecologic ...
Mar 25, 2022
0
10
A study led by researchers at The University of Texas MD Anderson Cancer Center reported that the MEK inhibitor trametinib reduced the risk of disease progression or death by 52% compared to standard-of-care therapies for ...
Feb 3, 2022
0
42
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that initial treatment with the PARP inhibitor veliparib in combination with chemotherapy significantly increased progression-free ...
Sep 28, 2019
0
6
